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 The transporters associated with 
antigen processing (TAP) allow the 
supply of peptides derived from the 
cytosol to translocate to the endoplasmic 
reticulum, where they complex with 
nascent human leukocyte antigen (HLA) 
class I molecules. However, infected and 
tumor cells with TAP molecules blocked 
or individuals with non-functional TAP 
complexes are able to present HLA class 
I ligands generated by TAP-independent 
processing pathways. These peptides are 
detected by the CD8
+
 lymphocyte cellular 
response. Herein, the generation of the 
overall peptide repertoire associated with 
four different HLA class I molecules in 
TAP-deficient cells was studied. Using 
different protease inhibitors, four 
different proteolytic specificities were 
identified. These data demonstrate the 
different allele-dependent complex 
processing pathways involved in the 
generation of the HLA class I peptide 
repertoire in TAP-deficient cells. 
The newly synthesized proteome is 
sampled continuously by CD8
+
 
lymphocytes as short peptides presented by 
human leukocyte antigen (HLA) class I 
molecules at the cell surface. The majority 
of the peptides presented by HLA class I 
molecules are produced from proteolysis by 
the proteasome and other cytosolic 
proteases, such as tripeptidyl peptidase II 
(1-3), puromycin-sensitive aminopeptidase 
(4), insulin degrading enzyme (5), thimet 
oligopeptidase (6), and caspases (7;8). 
These peptides are transported into the 
endoplasmic reticulum (ER) by TAP 
transporters, with subsequent N-terminal 
trimming by the metallo-aminoproteases 
ERAP1 and 2 frequently being required 
(9;10). Peptide binding to nascent HLA 
class I molecules generates stable 
peptide/HLA complexes that are exported 
to the cell membrane where are they 
exposed to cytotoxic CD8
+
 T lymphocyte 
recognition (reviewed in (11)).  
TAP
−/−
 humans (12) and mice (13) 
have a reduced functional CD8
+
 population 
but do not appear to have an increased 
susceptibility to neoplasms or viral 
infections. Thus, the TAP-independent 
pathways may be sufficient to control these 
diseases and allow individuals with this 
HLA class I deficiency to live normal life 
spans with only a limited susceptibility to 
chronic respiratory bacterial infections. In 
addition, evidence for TAP-independent 
pathways of antigen presentation by MHC 
class I molecules of particular but diverse 
pathogenic epitopes was previously 
reported (reviewed in (14-16)). The 
identified proteases involved in the 
generation of specific ligands in TAP-
deficient cells include ER signal peptidase 
(SPase) (17;18), ER signal peptide 
peptidase (SPPase) (19;20), trans-Golgi 
network furin (21;22), and lysosomal 
cathepsins (23). However, systematic 
studies of TAP-independent pathways 
involved in the generation of the overall 
peptide repertoire associated with different 
HLA class I molecules have not been 
reported. Studying the re-expression of 
newly synthesized complexes of different 




diverse protease inhibitors allowed the 
determination of several allele-dependent 
processing pathways in TAP-deficient cells. 
Experimental Procedures 
Cell lines- T2 is a TAP-deficient human 
cell line that express HLA-A2, -B51, and -
Cw1 class I molecules on the cell surface 
(24). T2-B27 cells were generated by 
transfection of T2 cells with HLA-B27 (a 
gift from Dr. David Yu, University of 
California,
 
Los Angeles, CA). T2 and T2-
B27 cells were cultured in RPMI 1640 
supplemented with 10% fetal bovine serum. 
Chemicals - Brefeldin A (BFA), 
chloroquine, and all protease inhibitors 
were from Sigma-Aldrich except leupeptin 
(Amersham-UBS), pepstatin (Boehringer 
Mannheim), butabindide (Tocris), 
decanoyl-Arg-Val-Lys-Arg-CMK (dec-
RVKR) (Bachem), (z-LL)2 ketone (Merck), 
and lactacystin (Dr. E. J. Corey, Harvard 
University). The general specificity and 
activity of all inhibitors used in this study 
are summarized in Table 1. At the 
concentrations indicated, no inhibitors were 
toxic as demonstrates the normal HLA class 
I re-expression of at least one allele for each 
inhibitor (see below). 
Acid stripping and HLA class I re-
expression - Cells were washed with RPMI 
in the absence of serum and incubated for 
90 s with ice-cool acid-stripping
 
medium 
(0.3 M glycine-HCl and 1% BSA in water, 
pH 2.4) as previously reported (25). Culture 
medium was added to neutralize the pH. 
Cells were washed three times, resuspended 
in assay medium (RPMI 1640 with 1% 
BSA) at 10
6
/ml, and incubated at 37ºC for 6 
h in the presence or absence of inhibitors at 
the indicated concentrations (Table 1). 
Serum-free conditions were used 
throughout.  
Flow cytometry - HLA expression levels 
were measured using the monoclonal 
antibodies (Abs) ME1 (anti-HLA-B27) (26) 
in T2-B27 cells; polyclonal H00003106-
B01P (specific for HLA-B class I 
molecules; Abnova) in T2 cells; and 
monoclonal PA2.1 (anti-HLA-A2) (27) and 
polyclonal SC-19438 (specific for HLA-C 
class I molecules; Santa Cruz 
Biotechnology) in T2 and T2-B27 cells 
simultaneously as previously described 
(28). Samples (104 cells) were run on a 
FACSCanto flow cytometer (BD 
Biosciences) and analyzed using CellQuest 
Pro 2.0 software (BD Bioscience). 
Percentage of inhibition of HLA re-
expression obtained by the addition of the 
indicated inhibitors (Table 1) was 
calculated utilizing the following equation: 
                    MFI+Inhibitor – MFI+2
nd
 Ab 
% Inhibition = 100  -    ---------------------------   x 100 
                                    MFIwithout Inhibitor – MFI+2
nd
 Ab 
Statistical analysis - To analyze statistical 
significance, an unpaired Student t test was 
used. P values < 0.01 were considered to be 
significant.  
RESULTS 
Endogenous processing of TAP-
independent HLA ligands. 
To examine the generation of the 
TAP-independent HLA-bound peptide 
repertoire, TAP-deficient T2 and T2-B27 
cells, treated with acid to remove surface 
class I peptide complexes, were allowed to 
re-express newly synthesized complexes for 
6 h. The T2-B27 cell line was selected 
because it expresses one each of the 
endogenous HLA-A, -B, and –C alleles and 
an additional HLA-B class I molecule, thus 
mimicking a partial heterozygous 
haplotype. This expression pattern allows 
four different class I molecules to be 
studied.  As previously reported for some 
MHC class I alleles (29), different re-
expression levels were found in each of the 
four HLA class I molecules studied (Fig. 1, 
upper panel). To test if TAP-independent 
ligands require endogenous processing, 
HLA re-expression was analyzed in the 
presence of BFA. This drug blocks class I 
export beyond the cis-Golgi compartment 
(30;31), preventing the surface expression 
of newly assembled class I-peptide 
complexes from endogenous origin. The re-
expression level of all four HLA class I 




used was significantly decreased: 84% ± 
10% for HLA-A2, 87% ± 8% for HLA-
B27, 80% ± 7% for HLA-B51 and 63% ± 
8% for HLA-Cw1 (Fig. 1). These results 
demonstrated that the generation of the 
TAP-independent HLA-ligands was 
generated primarily from proteins 
endogenously processed in TAP-deficient 
cells. 
Proteasome inhibitors differentially 
affect the TAP-independent expression of 
distinct HLA class I molecules. 
To study the involvement of 
different proteolytic activities in the 
generation of TAP-independent ligands 
presented by HLA class I molecules, the 
surface re-expression of different HLA 
class I molecules after acid stripping in T2-
B27 TAP-deficient cells was performed in 
the presence or absence of different 
inhibitors. Previously, partial block (~ 50% 
of inhibition) of HLA-A2 re-expression in 
TAP-deficient cells caused by the addition 
of lactacystin (LC), a Streptomyces 
metabolite (32-34) (Table 2), demonstrated 
a role for proteasomes in HLA class I 
processing of TAP-independent HLA-A2 
ligands (25). The involvement of 
multicatalytic complex proteasome in the 
processing of ligands presented by other 
HLA class I was studied.  Both LC and 
epoxomicin (35;36), another proteasome 
inhibitor, partially block both HLA-A2 and 
–B51 re-expression (Fig. 2), implicating the 
proteasomes in the generation of HLA 
ligands presented by these alleles By 
contrast, in the same experiment, both 
proteasome inhibitors have no effect on the 
re-expression of HLA-B27 and -Cw1 class I 
molecules. Thus, these data indicate that the 
proteasome activity is not absolutely 
required to generate ligands bound to HLA-
B27 and –Cw1 class I molecules. 
Metallo-aminopeptidases inhibitor 
specifically blocks the TAP-independent 
expression of peptide-HLA-A and –B but 
not -C complexes. 
To characterize proteases distinct 
from proteasomes that may contribute to 
processing of HLA ligands, experiments 
with several specific protease inhibitors 
were performed. Leupeptin (LEU) (37), 
pepstatin (PEPST) (37;38), E64 (39), and 
1,10-phenanthroline (PHE) (38;40) 
inhibitors were initially tested because they 
are specific for different protease families 
(Table 1) and cover a wide range of 
protease classes. These three inhibitors had 
no effect on the HLA re-expression of any 
of the four alleles studied (Fig. 3). Thus, the 
enzymes inhibited by these drugs cannot be 
formally involved in the generation of TAP-
independent ligands. 
In addition, as the activity of 
ERAP, an enzyme previously involved in 
antigen processing (41;42), is not fully 
blocked by PHE at the concentration used 
in this study, the inhibitor leucinethiol 
(LeuSH) (Table 2) (43) was used. A partial 
inhibition of surface re-expression of HLA-
A2 (38% ± 4%), -B27 (36% ± 10%), and –
B51 (48% ± 8%) but not HLA-Cw1 (0% ± 
5%) in TAP-deficient cells treated with 
LeuSH was found (Fig. 3). These 
inhibitions are similar to those previously 
reported in TAP-sufficient cells, where the 





, decreased between 
20 and 40% by specific ERAP inhibition 
(43). Thus, these data implicate ERAP, or 
other metallo-aminopeptidases, in the 
generation of a subset of TAP-independent 
ligands presented by three of four HLA 
class I molecules examined. 
SPPase is involved in the generation of 
TAP-independent HLA-A2, and –B51 
ligands 
Different proteases such as 
tripeptidyl peptidase II (1;2), puromycin-
sensitive aminopeptidase (4), and furin 
(21;22) were previously implicated in 
antigen processing as being able to generate 
pathogen-derived peptides. The possible 
role of these enzymes in endogenous 
presentation of TAP-independent ligands 
was studied using available specific 
inhibitors (Table 1). Inhibition of HLA re-
expression was not detected with any of 
these drugs (Fig. 4) in all HLA class I 
alleles studied, and thus, the enzymatic 
activity of these peptidases is not absolutely 






independent HLA-A2 class I ligands are 
derived by cleavage of the respective signal 
sequences generated by the SPase complex 
(16;44). A specific inhibitor of this 
enzymatic activity is unavailable; thus, 
direct involvement of SPase complex in the 
generation of TAP-independent HLA-A2 
ligands could not be studied. However, two 
SPase-processed peptides need further 
cleavage by SPPase (19;20), allowing the 
hypothetical involvement of SPPase to be 
examined by treating TAP-deficient cells 
with the SPPase-specific inhibitor (z-LL)2 
ketone (19;20). This drug specifically 
inhibits TAP-independent HLA re-
expression of HLA-A2 (82% ± 10%), and –
B51 (48% ± 10%), but not –B27 (10% ± 
7%) or -Cw1 (1% ± 12%). These results 
demonstrate the role of SPPase in the 
generation of TAP-independent ligands for 
some HLA class I molecules. 
TAP-independent expression of peptide-
HLA-B27 complexes is chloroquine 
(CQ)-sensitive. 
Previously, three epitopes processed in an 
endosomal/lysosomal antigen processing 
pathway for murine MHC class I 
presentation in TAP-deficient cells were 
blocked in cells treated with CQ (23;45;46). 
Thus, the contribution of the CQ-sensitive 
(47;48) processing pathway to the 
generation of overall TAP-independent 
ligands was evaluated. In our experiments, 
specific reduction (41% ± 8%) of the HLA-
B27 surface levels in presence of CQ was 
detected (Fig. 4). In contrast, the re-
expression of HLA-A2, -B51, and –Cw1 
class I molecules was not altered by this 
drug (Fig. 4). These data indicate that the 
endosomal/lysosomal antigen-processing 
pathway is HLA class I allele-dependent. 
Summary of inhibitions of HLA class I 
re-expression. 
With the drugs used in this study 
(Table 1), three different inhibition patterns 
of HLA class I expression were found 
(summarized in Table 2). The inhibition 
obtained in all HLA-class I alleles 
examined in presence of BFA indicates that 
most of the TAP-independent HLA-bound 
peptides were endogenously processed. The 
surface levels of HLA-A2 and –B51 class I 
were dependent on proteasome, metallo-
aminopeptidases (probably ERAP), and 
SPPase activities. Metallo-aminopeptidases 
and CQ-sensitive processing are relevant 
for generating HLA-B27 ligands. By 
contrast, none of the compounds used in 
this study decreased HLA-Cw1 surface 
expression. 
DISCUSSION 
 This study was undertaken to 
compare the generation of the peptide 
repertoire associated with four different 
HLA class I molecules in TAP-deficient 
cells. Previously, the expression of various 
HLA class I molecules were differentially 
affected by proteasome inhibitors in TAP-
sufficient cells (25). These inhibitors 
blocked the re-expression of HLA-A2 
(60%) and -B51 (80%) class I molecules. In 
contrast, HLA-B27 was largely insensitive 
to proteasome inhibitors (only 30% of 
inhibition of re-expression) (25). In the 
same study, the role of the proteasome in 
processing TAP-independent HLA-A2 
ligands was reported (25). We found that a 
different MHC class I molecule, HLA-B51, 
is also proteasome-dependent in the 
generation of the HLA peptide repertoire in 
TAP-deficient cells. In addition, the 
proteasome inhibitors have no effect on the 
expression of TAP-independent 
peptide/HLA-B27 or –Cw1 repertoires. 
Thus, differential involvement of the 
proteasome in the generation of ligands 
bound to HLA class I molecules was found 
in this study. There was a direct correlation 
of the role of proteasomes in the processing 
of HLA peptide repertoires of TAP-
dependent and –independent ligands 
between TAP-sufficient and deficient cells. 
The role of SPase in the processing 
of TAP-independent presented HLA-A2 
peptides has been found previously 
(17;18;44). Moreover, SPPase catalyzes 
intra-membrane proteolysis of two signal 
peptides after they have been cleaved from 
a pre-protein as the signal sequence-derived 
HLA-E peptides (19;20). Thus, sequential 
cleavage by SPase and SPPase was 




peptides. We found that the specific 
inhibitor for SPPase activity significantly 
decreased the HLA expression of some 
alleles in TAP-deficient cells involving 
these sequential enzymatic activities in the 
processing of TAP-independent ligands 
bound to HLA-A2 and –B51 class I 
molecules. 
It is well documented that trimming 
of ligand precursors in the endoplasmic 
reticulum (ER) is important for the 
generation of appropriate peptides for HLA 
class I binding and that ER-resident 
aminopeptidase activity has an important 
impact on the repertoire of ligands 
presented in TAP-sufficient cells (reviewed 
in (49)). The present study demonstrates 
that metallo-aminoprotease-sensitive 
trimming is also required to generate TAP-
independent ligands presented by different 
HLA class I molecules. 
HLA-A2 and –B51 class I 
molecules demonstrated a similar HLA-
expression inhibition pattern involving the 
proteasome, SPPase, and metallo-
aminopeptidase enzymatic activities in the 
generation of TAP-independent ligands. 
Thus, the most likely explanation is 
summarized via the following model. 
Multiple endogenous proteins are 
proteolyzed by the proteasome in the 
cytosol. Some of the generated peptides are 
released into the ER as indicated by the 
presentation in some instances of cytosolic 
proteins in cells lacking TAP (50;51). This 
presentation of peptides could occur by 
passive diffusion (52), hydrophobic 
peptides with specific ability to traverse 
membranes (53), or unidentified transport. 
In parallel, SPase releases peptides with 
signal sequence into the ER. Lastly, a 
fraction of total ER-peptides could be 
processed by SPPase activity and/or ERAP 
trimming prior to their binding to HLA-A2 
or –B51 molecules.  
The presentation pathway for 
extracellular antigens requires endocytosis 
and degradation in endolysosomal 
compartments. HLA class II molecules bind 
the peptides generated and these complexes 
are transported to the cell surface (54). 
Reagents that prevent endosomal 
acidification block this type of processing, 
inhibiting the protein cleavage by 
endosomal enzymes, such as the acidophilic 
amine CQ. Previously CQ-sensitive 
endosomal processing of internalized 
endogenous transmembrane proteins (23) or 
viral particles (45) for the generation of 
murine MHC class I-binding peptides was 
reported. The current study shows the 
formation of the overall TAP-independent 
peptide/HLA-B27 complexes by a 
proteasome-independent but BFA- and CQ-
sensitive pathway. These data imply that 
class I molecules on the cell surface are 
internalized to an endolysosomal 
compartment where they intersect with 
peptides either supplied by the lysosomal 
polypeptide transporter TAPL (reviewed in 
(55)) or those directly processed by 
lysosomal proteases. In addition, some of 
these HLA-B27-restricted peptides need 
further trimming by metallo-
aminopeptidases sensitive to LeuSH. 
In addition, inhibition of the HLA-
Cw1 surface expression was not detected 
with the chemicals used in this study. Thus, 
the identification of the different 
peptidase(s) of the antigen-processing 
pathway involved in the generation of 
HLA-Cw1 ligand awaits further molecular 
and cellular biology studies.  
In summary, different and complex 
processing pathways involving at least four 
diverse proteolytic specificities in 
miscellaneous subcellular locations are 
required to generate the HLA class I 
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FIGURE LEGENDS 
Figure 1.  
Surface re-expression of HLA class I molecules after acid stripping in the presence of 
BFA. 
T2 and T2-B27 cells were untreated (filled bars) or incubated with 5 g/ml BFA for 6 h (thick 
bars) after acid washing. Stability at the cell surface of HLA-A2, -B27, -B51, and –Cw1 class I 
molecules of the TAP-deficient cells was measured by flow cytometry using  monoclonal Ab 
ME1 (anti-HLA-B27) in T2-B27 cells; polyclonal H00003106-B01P (specific for HLA-B class 
I molecules) in T2 cells; and monoclonal Abs PA2.1 (anti-HLA-A2) and polyclonal SC-19438 
(specific for HLA-C class I molecules) in T2 and T2-B27 cells simultaneously. The data are 
expressed as MFI ± SD (upper panel) or percentage of inhibition ± SD (lower panel) of HLA 
surface re-expression in presence of BFA and are the means of three-four different experiments.  
Figure 2.  
 
Effect of several proteasome inhibitors on surface re-expression of HLA class I molecules 
after acid washing. 
 
T2 and T2-B27 cells as in Figure 1 were incubated with LC (open bars) or EPOX (filled bars) at 
the indicated concentrations (Table 1) as in Figure 1. The data are expressed as percentage of 
inhibition ± SD as in Figure 1 and are the means of four-five different experiments. 
 
Figure 3.  
Surface re-expression of HLA class I molecules after acid stripping in the presence of 
several protease classes inhibitors. 
T2 and T2-B27 cells as in Figure 1 were incubated with the indicated inhibitors at the 
concentrations summarized in Table 1. HLA-A2 (filled bars), -B27 (open bars), -B51 (right 
thick bars), and –Cw1 (left thick bars) surface re-expression was measured. The data are 
expressed as percentage of inhibition ± SD as in Figure 1 and are the means of three-six 
different experiments. A representative experiment with T2 cells stained with anti-HLA-A2 Ab 
was depicted in the bottom panel. The coded used as in follows: second Ab alone (negative 
control, shaded histogram), no inhibitor (thin line) and 30 M LeuSH (thick line). 
 
Figure 4.  
Outcome of different protease-specific inhibitors or a lysosomotropic agent on surface re-
expression of HLA class I molecules after acid washing.  
T2 and T2-B27 cells as in Figure 1 were incubated with the indicated drugs at the 
concentrations summarized in Table 1.  HLA-A2 (filled bars), -B27 (open bars), -B51 (right 




expressed as percentage of inhibition ± SD as in Figure 1 and are the means of three-six 
different experiments. A representative experiment with T2 cells stained with anti-HLA-A2 Ab 
was depicted in the bottom panel. The coded used as in follows: second Ab alone (shaded 








General specificity of inhibitors used in this study 
 
Inhibitor Abbreviation Specificity Reference Concentration 
     
Brefeldin A BFA Vesicle transport  (30;31) 5 g/ml 
Lactacystin LC Proteasome chymotryptic and tryptic activities (32-34) 10 M 
Epoxomicin EPOX Proteasome chymotrypsin-like activity (35;36) 1 M 
E64 E64 Cysteine proteases C1 (39) 100 M 
Leupeptin LEU Trypsin-like proteases and cysteine proteases (37) 100 M 
Pepstatin PEPST Aspartic proteases (37;38) 100 M 
1-10 Phenanthroline PHE Metalloproteases and caspase-1 (38;40) 50 M 
Leucinthiol Leu-SH Metallo-aminopeptidases including ERAAP  (43) 30 M 
Butabindide BUT Tripeptidyl peptidase II (56) 100 M 
Puromycin PUR 
Dipeptidyl-peptidase II and  puromycin-sensitive 
aminopeptidase 
(57) 0.5 g/ml 
Decanoyl-Arg-Val-Lys-Arg-CMK dec-RVKR Furin and other members of the SPC family (58) 100 M 
(z-LL)2 ketone z-LL2 Signal peptide peptidase (19;20) 
100 M 
Chloroquine CQ Lysosomotropic agent  (47;48) 50 M 











 LC/EPOX LeuSH z-LL2 CQ 
      
HLA-A2 +
b
 + + + - 
HLA-B27 
+ - + - + 
HLA-B51 
+ + + + - 
HLA-Cw1 + - - - - 
      
 
a
 For specificity of different inhibitors see Table 1. 
b
 + and - indicate % inhibition > 35% and < 10%, respectively. All + inhibitions show 
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